Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C Navada,Guillermo Garcia-Manero,Ehab L Atallah,M Nabeel Rajeh,Jamile M Shammo,Elizabeth A Griffiths,Samer K Khaled,Shaker R Dakhil,David E Young,Rosalie Odchimar-Reissig,Naveen Pemmaraju,Yesid Alvarado,Maro N Ohanian,Rosmy B John,Patrick S Zbyszewski,Manoj Maniar,Michael E Petrone,Steven M Fruchtman,Lewis R Silverman

doi:10.1182/blood-2018-99-119259

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Shyamala C Navada, Guillermo Garcia-Manero + Show 17 more

Open Access

https://doi.org/10.1182/blood-2018-99-119259

Copy DOI

Journal: Blood	Publication Date: Nov 29, 2018
Citations: 10

Affiliation: Icahn School of Medicine at Mount Sinai, The University of Texas MD Anderson Cancer Center, Medical College of Wisconsin, St. Louis Medical Clinic, Rush University, Roswell Park Cancer Institute, City of Hope, Cancer Center of Kansas, Onconova Therapeutics (United States), New York Oncology Hematology

#Research Funding #Onconova Therapeutics + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naïve & Relapsed (Rel)/Refractory (Ref) Patients

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.